• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Editor's Pick

Biden’s pandemic playbook failed. Trump just offered a smarter path forward

by May 15, 2025
written by May 15, 2025
NEWYou can now listen to Fox News articles!

On May 5, President Donald Trump signed an executive order outlawing future federal funds going to gain-of-function research. This move comes as the nation begins to reckon with the broader failures of its pandemic response – failures that extended far beyond the lab and into every aspect of public health policy.

As the acute phase of the COVID-19 pandemic fades into the rearview mirror, the United States finds itself engaged in postmortems: on lockdowns, vaccines, school closures and public trust. But there’s one glaring lesson the U.S. has yet to fully absorb – its health strategy during crises can’t rely on just one type of tool. A narrow, binary response to COVID-19 cost lives. The country must do better next time.

During the pandemic, the public was often presented with a simple directive: get vaccinated or take your chances. While most Americans indeed should have gotten vaccinated, policymakers should have provided more room for nuance and variation. They ignored a core truth of medicine – no single solution fits every individual. The virus evolved. Patient responses varied. But the official toolkit did not adapt.

What the U.S. needed (and still needs) is a robust, flexible public health approach that supports a range of modalities: vaccines, yes, but also antivirals, monoclonal antibodies (mAbs) and emerging biologics. 

A resilient system is one that can pivot quickly, match patients with the right intervention and adapt as science advances.

Monoclonal antibodies offer a clear example of what went wrong. These therapies, proven to reduce hospitalizations and deaths among high-risk patients, were widely distributed early in the pandemic and used successfully by top federal officials, including the president. But in late 2021 and early 2022, federal authorities stopped distributing them, citing reduced efficacy against new variants.

This was a mistake. mAbs are a platform technology. They can be tailored to variants and deployed quickly. They are especially important for those who don’t respond well to vaccines. But nearly five years after the start of the pandemic, no mAb has received full FDA approval for respiratory virus prevention despite meeting the same safety and efficacy benchmarks used to fast-track other medical countermeasures. 

Meanwhile, the public was encouraged to rely on booster shots which, while still additive, lost efficacy as the pandemic continued. CDC data show that the bivalent booster provided only 37% protection against hospitalization for adults over 65 after several months. For the immunocompromised, protection was even lower. Yet, therapies that could have closed that gap were taken off the table.

The U.S. should have maintained an all-of-the-above approach to treatment so its health professionals could make patient recommendations on a case-by-case basis, ensuring the most vulnerable Americans receive adequate protection. 

More broadly, five years later, the U.S. still lacks a proactive framework for deploying flexible, evidence-driven therapeutics in a public health emergency. The U.S. needs a system that doesn’t just rely on whatever is first to market; it needs one that actively supports a diversified portfolio of tools.

That means empowering agencies like the Biomedical Advanced Research and Development Authority and the National Institutes of Health to invest in adaptable countermeasures – antibody platforms, broad-spectrum antivirals, rapid diagnostics and therapeutic RNA technologies. It also means modernizing the FDA’s approval pathways to reflect the pace of innovation. When real-world evidence shows that a therapy is saving lives, regulators should have the flexibility to act.

Congress can help by authorizing funding streams that reward versatility, creating incentives for companies to maintain and adapt an all-of-the-above treatment approach, and ensuring public-private partnerships are built for speed and scale. Legislation could also establish a standing procurement mechanism for variant-specific updates, not just vaccines.

All of this will help to mitigate the damage of one of the greatest casualties of the pandemic – the decline of public trust in America’s health institutions. This erosion stemmed from the sense that key decisions lacked transparency or failed to account for patients’ diverse needs.

According to a 2022 Pew Research Center survey, only 29% of U.S. adults said they had a great deal of confidence in medical scientists, down from 40% at the beginning of the pandemic. Trust in public health officials followed a similar decline.

A more transparent, inclusive approach, where policymakers communicate the rationale behind treatment shifts and openly assess real-world outcomes, can help rebuild that trust. A better system would emphasize data-sharing, clear communication, and respect for physician judgment in tailoring care to patient needs.

COVID-19 exposed the limits of the U.S.’ current playbook. A more effective future demands flexibility, pluralism and the humility to admit health policymakers don’t always know right away what will work best, or for whom. 

But if regulators build the right system – one that encourages innovation, evaluates outcomes in real time, and keeps every safe and effective tool on the table – they won’t have to learn this lesson again the hard way.

This post appeared first on FOX NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
YouTube will stream NFL Week 1 game in Brazil for free
next post
Trump makes historic UAE visit as first US president in nearly 30 years

related articles

Biden camp skipped Super Bowl interview amid Robert...

August 8, 2025

Steve Bannon has two-word answer to dismiss 2028...

August 7, 2025

Biden camp skipped Super Bowl interview amid Robert...

August 7, 2025

$93 million in aid to fight malnutrition headed...

August 7, 2025

Who is Anita Dunn? The Biden confidante who...

August 7, 2025

Republican senator claims RFK Jr. mRNA vaccine decision...

August 7, 2025

Veteran Biden insider Anita Dunn appears in House...

August 7, 2025

Veteran Biden insider Anita Dunn to appear in...

August 7, 2025

Trump-Putin meeting agreed upon ‘in principle,’ Kremlin aide...

August 7, 2025

Junk food banned from SNAP benefits in 6...

August 7, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Left-wing billionaires bankroll Dem super PAC plotting to win back working-class voters: ‘This is a priority’

    February 4, 2025
  • China going after down-ballot races: report reveals which lawmakers are in their crosshairs

    October 24, 2024
  • Kraft Heinz to remove artificial dyes from U.S. products by end of 2027

    June 17, 2025
  • House GOP campaign chair makes prediction for 2026 midterms: ‘Going to be on offense’

    December 19, 2024
  • Dental supply stock surges on RFK’s anti-fluoride stance, activist involvement

    November 19, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (5,660)
  • Investing (634)
  • Stock (876)

Latest Posts

  • Chinese stocks surge on AI optimism, nearing three-year highs

    February 14, 2025
  • Is BP Share Price Undervalued? A Buyer’s Guide

    August 13, 2024
  • Trump 1.0 alums share chilling Google message from before second-term return: ‘LAWFARE at its finest’

    August 2, 2025

Recent Posts

  • Jimmy Carter’s funeral brings all 5 living presidents together in Washington, DC

    January 9, 2025
  • Two Republicans vote against Trump’s $9 billion clawback of foreign aid, NPR funding

    July 17, 2025
  • China exerts new restrictions on exports of minerals critical to US weapons making

    September 17, 2024

Editor’s Pick

  • Encircling Taiwan was a smokescreen for China’s real goal of convincing US not to intervene, expert says

    October 20, 2024
  • Vice President JD Vance to play key role with RNC to ‘fully enact MAGA mandate,’ grow GOP majority in 2026

    March 18, 2025
  • AUDUSD and AUDNZD: AUDUSD is  under pressure on Friday

    August 9, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock